South Africa on Track to Receive Full Vaccine Orders This Year
(Bloomberg) -- South Africa is on track to receive enough Covid-19 vaccines to cover about two-thirds of the population by the end of the year, made up of both Pfizer Inc. and Johnson & Johnson doses.
The country has secured orders for 52.6 million shots, including 31.2 million of the single-dose J&J version, President Cyril Ramaphosa told parliament on Thursday. They are due to be delivered gradually over the rest of the year, although about half won't arrive until after September, he said.
“The estimated times for the delivery of the vaccines depends on several factors, many of which are beyond our control,” he said.
The schedule is as follows:
- 2Q: 5.9 million Pfizer doses, 3 million J&J
- 3Q: 8.5 million Pfizer, 9.1 million J&J
- 4Q: 7 million Pfizer, 19.1 million J&J
South Africa has been criticized for a slow start in securing orders for Covid-19 vaccines, which were held up in part by negotiations over issues such as indemnity clauses, a way of protecting the drugmakers from legal claims arising from adverse side-effects.
Patent Protections
Pharmaceutical companies were also pushing the government to ease back on a campaign for the loosening of vaccine patent protections, a person familiar with the situation said last month. The U.S. lent its support to that proposal this week, increasing the chances that a deal can be reached among World Trade Organization members.
“It should be noted that negotiations with the manufacturers were protracted as we had to ensure that the terms of the contracts were consistent with our laws and were not detrimental to our national interest,” Ramaphosa said.
South Africa wants to step up the country's vaccine-manufacturing capability to prepare for future pandemics and that's why it's pushing for intellectual-property waivers, the president said.
Read More: African Leaders Seek Vaccine-Making Sites to Counter Inequality
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.